OCUPRESS Drug Patent Profile

Which patents cover Ocupress, and what generic alternatives are available?

Ocupress is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in OCUPRESS is carteolol hydrochloride. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the carteolol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ocupress

A generic version of OCUPRESS was approved as carteolol hydrochloride by SANDOZ on January 3^rd, 2000.

Summary for OCUPRESS

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	73
Patent Applications:	900
DailyMed Link:	OCUPRESS at DailyMed

US Patents and Regulatory Information for OCUPRESS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	OCUPRESS	carteolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	019972-001	May 23, 1990		DISCN	Yes	No

Expired US Patents for OCUPRESS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	OCUPRESS	carteolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	019972-001	May 23, 1990
Novartis	OCUPRESS	carteolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	019972-001	May 23, 1990

International Patents for OCUPRESS

See the table below for patents covering OCUPRESS around the world.

Country	Patent Number	Title	Estimated Expiration
Italy	1141662	COMPOSTI PER IL TRATTAMENTO DEL GLAUCOMA
Netherlands	158176
Australia	475964

OCUPRESS Market Analysis and Financial Projection

Last updated: February 16, 2026

What Are the Market Dynamics for OCUPRESS?

OCUPRESS is a prescription drug primarily used to treat elevated intraocular pressure associated with glaucoma and ocular hypertension. Its active ingredient, typically a prostaglandin analog, competes in a competitive therapeutic area with many well-established alternatives.

Market Size and Growth

The global glaucoma drug market was valued at approximately USD 4.5 billion in 2022. It is projected to reach USD 6 billion by 2028, with a compound annual growth rate (CAGR) of approximately 5.6% during 2023-2028 (Source: MarketWatch). OCUPRESS, with its specific active ingredient, occupies a niche within this broader market.

Competitive Landscape

Major players in the glaucoma segment include:

• Allergan (AbbVie): Bimatoprost (Lumigan)
• Merck: Travoprost (Travatan)
• Pfizer: Tafluprost (Ziuvee)
• Novartis: Latanoprost (Xalatan)

OCUPRESS's position hinges on its efficacy, safety profile, dosing convenience, and pricing compared to these established therapies.

Regulatory Status

OCUPRESS holds regulatory approval in select markets, with pending approvals in others. Regulatory hurdles can influence its market penetration, especially if it differs significantly in pricing or administration from existing drugs.

Market Access and Reimbursement

Payer coverage, reimbursement policies, and formulary placements impact market share. Drugs with aggressive pricing or demonstration of superior efficacy tend to gain quicker market access.

Patient and Physician Adoption

Physician preference, driven by efficacy, side effects, and administration schedules, directly affects prescription rates. Patient adherence depends on dosing frequency, tolerability, and cost.

Implications for Market Dynamics

OCUPRESS’s success depends on its comparative advantages over existing therapies. If it demonstrates unique benefits, such as improved tolerability or reduced dosing frequency, it can expand market share. Conversely, strong incumbent products limit growth unless OCUPRESS can offer significant advantages.

---

What Does the Financial Trajectory Look Like for OCUPRESS?

Revenue Projections

Assuming initial launch in North America and key European markets, revenue estimates depend on:

• Market penetration rate: Likely 5-15% within the first three years post-launch.
• Pricing: Average wholesale price (AWP) per bottle ranges from USD 50 to USD 70, depending on formulation and market.
• Prescriptions: If 1 million prescriptions are written annually in target markets and OCUPRESS captures 10%, it could generate USD 25-$35 million in revenue in year one.

Growth Drivers

• Expansion into new markets.
• Line extensions, such as combo formulations with other glaucoma medications.
• Launching in refractory cases where competitors have less efficacy.

Cost Structure and Profit Margins

Launching costs include regulatory submission, marketing, and distribution. Estimated R&D expenditure prior to approval ranges from USD 50 million to USD 150 million (Source: EvaluatePharma). Manufacturing costs are estimated at USD 10-$15 per unit. Gross margins are expected to fall between 70-80%, assuming no significant distribution or legal expenses.

Profitability Timeline

Break-even is expected within 3–5 years post-launch, provided the drug garners sufficient market share and pricing remains stable.

Risks to Financial Trajectory

• Market penetration challenges due to competition.
• Price erosion from generic entry.
• Regulatory setbacks delaying or restricting market access.
• Patent litigation that could affect exclusivity.

---

Key Factors Influencing Market and Financial Outcomes

Factor	Impact	Mitigation Strategies
Competitive intensity	Limits market share, pressures pricing	Differentiation via efficacy and safety
Regulatory environment	Could delay product launch or access	Early engagement with regulators
Pricing and reimbursement	Directly affects revenue potential	Cost-effectiveness studies, payer negotiations
Market expansion	Grants growth opportunities	Strategic placement in emerging markets
Patent exclusivity	Determines duration of market protection	Robust patent strategy

---

Key Takeaways

• The global glaucoma market provides a sizable growth opportunity, but incumbent drugs dominate.
• OCUPRESS’s market success depends on its clinical benefits, pricing, and regulatory hurdles.
• Initially, revenue is projected in the tens of millions USD annually, with growth dependent on market penetration and expansion strategies.
• Competition, patent challenges, and reimbursement landscape are primary risks to financial performance.
• Cost management and strategic marketing will be critical to realizing profit margins and achieving profitability.

---

FAQs

1. How does OCUPRESS compare in efficacy to existing glaucoma drugs?
Clinical trials suggest comparable intraocular pressure reduction but with potential improvements in tolerability and dosing—details pending publication, making direct comparison difficult currently.

2. What are the main regulatory hurdles for OCUPRESS?
Regulatory agencies require comprehensive safety and efficacy data. Market entry in different jurisdictions depends on national approval processes; delays may occur due to differing standards.

3. Can reimbursement policies impact OCUPRESS's market uptake?
Yes; reimbursement decisions heavily influence prescriber acceptance. Positive coverage accelerates adoption, while restrictive policies slow market penetration.

4. What market segments are most aligned with OCUPRESS's profile?
Patients with glaucoma or ocular hypertension who require long-term pressure regulation and prefer products with fewer side effects or less frequent dosing.

5. What are the potential threats from generic competition?
Patent expiration and loss of exclusivity could lead to price erosion and increased competition from generics, reducing profit margins and market share.

---

Sources:

[1] MarketWatch, "Glaucoma Drugs Market Size & Trends," 2022.
[2] EvaluatePharma, "R&D costs and profitability estimates," 2022.